Expanded Analysis of a Modified Enhanced Recovery Protocol in Cleft Palatoplasty.

Autor: Hush SE; Center for Cleft and Craniofacial Disorders, Children's Healthcare of Atlanta, GA, USA., Brady C; Center for Cleft and Craniofacial Disorders, Children's Healthcare of Atlanta, GA, USA., Soldanska M; Center for Cleft and Craniofacial Disorders, Children's Healthcare of Atlanta, GA, USA., Williams JK; Center for Cleft and Craniofacial Disorders, Children's Healthcare of Atlanta, GA, USA.
Jazyk: angličtina
Zdroj: The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association [Cleft Palate Craniofac J] 2020 Oct; Vol. 57 (10), pp. 1190-1196. Date of Electronic Publication: 2020 Jun 22.
DOI: 10.1177/1055665620932000
Abstrakt: Objective: We have previously shown the efficacy of an enhanced recovery after surgery (ERAS) protocol in pediatric cleft palatoplasty for proof of concept (POC). We sought to validate the efficacy of ERAS when expanded to patients of variable age and complexity undergoing primary palatoplasty.
Main Outcome Measure(s): Between April 2017 and December 2018, 100 patients were collected prospectively for the expanded assessment (ERAS 2 ) and POC (ERAS 1 ) and compared to historical controls both independently and in aggregate (ERAS (T) ). We compared patient demographics, perioperative narcotic administration, length of stay (LOS), and rates of return to service (RTS).
Results: Despite increased complexity, total narcotic usage (morphine equivalents normalized per weight) during each phase of care was significantly greater in controls when compared to ERAS 1 , ERAS 2 , or ERAS T , respectively (intraoperative: 0.44 mg/kg vs 0.013 mg/kg vs 0.016 mg/kg vs 0.014 mg/kg; postanesthesia care unit: 0.061 mg/kg vs 0.006 mg/kg vs 0.007 mg/kg vs 0.007 mg/kg; postoperative: 0.389 mg/kg vs 0.009 mg/kg vs 0.026 mg/kg vs 0.017 mg/kg). ERAS 1 and ERAS 2 groups each demonstrated a decrease in LOS (-36.6%, -26.3%) when compared to controls. Overall, application of ERAS led to a 95.7% reduction in narcotic administration and a 31.7% decrease in LOS when compared to controls. The incidence of RTS was higher in ERAS 2 (13.0%) when compared to ERAS 1 (2.1%) or controls (2.4%), with the strongest independent predictor being a positive perioperative respiratory viral panel (PRVP).
Conclusions: Application of ERAS to palatoplasty patients of advanced age and complexity evidenced consistency with respect to decreased perioperative narcotic administration and shortened LOS. A positive PRVP was found to be an independent predictor of RTS even when ERAS was applied.
Databáze: MEDLINE
Externí odkaz: